WASHINGTON and LA JOLLA, Calif., Dec. 3 /PRNewswire-FirstCall/ -- ICx Technologies (Nasdaq: ICXT), a developer of advanced technology solutions for homeland security and force protection, announced today a research study with Merck & Co., Inc. and Fred Hutchinson Cancer Research Center of Seattle .
The purpose of the study is to test and refine a set of protocols for detecting and recovering circulating nucleic acids from blood -- a key early detector for cancer treatment - in order to support the development of an investigational cancer therapy. The study is being conducted by its La Jolla, Calif.-based Biosystems unit with participation by the Hutchinson Center.
"We have a history of aggressive research and development expertise and we're pleased to work with Merck," said ICx CEO Hans Kobler . "By applying the rapid and data-rich molecular diagnosis technology developed for security applications, ICx is hoping to aid the development of a diagnostic tool to assist in the evaluation of cancer therapies."
For more information, visit www.icxt.com.
About ICx Technologies(TM)
ICx develops advanced technologies for effective security solutions. ICx sensors detect and identify chemical, biological, radiological, nuclear and explosive (CBRNE) materials. ICx surveillance products discern people and objects invisible to human senses and conventional cameras. ICx software and systems connect, command and control these security devices, while its intelligence and special-operations experts provide the unique insight that drives the company's innovation. ICx has manufacturing and research facilities in the United States , Canada and Europe .
Statements contained in this press release that are not historical facts are "forward-looking statements" within the meaning of the federal securities laws. Forward-looking statements, including statements relating to ICx Technologies' plans, objectives and expectations for future operations, are uncertain and subject to a variety of risks that could cause actual results to differ materially from those expected by ICx Technologies. You should consider the risk factors described in ICx Technologies' prospectus as filed with the U.S. Securities and Exchange Commission on November 8, 2007 , as well as other filings. ICx Technologies undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.
All trademarks, registered trademarks and service marks are the property of their respective owners.
SOURCE ICx Technologies